ATE450547T1 - Eml4-alk-fusionsgen - Google Patents
Eml4-alk-fusionsgenInfo
- Publication number
- ATE450547T1 ATE450547T1 AT07254044T AT07254044T ATE450547T1 AT E450547 T1 ATE450547 T1 AT E450547T1 AT 07254044 T AT07254044 T AT 07254044T AT 07254044 T AT07254044 T AT 07254044T AT E450547 T1 ATE450547 T1 AT E450547T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion gene
- cancer
- present
- eml4
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006277718 | 2006-10-11 | ||
| JP2007120670 | 2007-05-01 | ||
| CA 2598893 CA2598893C (en) | 2006-10-11 | 2007-08-24 | Eml4-alk fusion gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450547T1 true ATE450547T1 (de) | 2009-12-15 |
Family
ID=39277176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07254044T ATE450547T1 (de) | 2006-10-11 | 2007-10-11 | Eml4-alk-fusionsgen |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7728120B2 (de) |
| EP (1) | EP2116553B1 (de) |
| JP (2) | JP4303303B2 (de) |
| AT (1) | ATE450547T1 (de) |
| CA (1) | CA2598893C (de) |
| DE (1) | DE602007003543D1 (de) |
| ES (2) | ES2515170T3 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| WO2008127248A1 (en) * | 2007-04-13 | 2008-10-23 | Cell Signaling Technology, Inc. | Gene defects and mutant alk kinase in human solid tumors |
| ES2637592T3 (es) | 2006-04-14 | 2017-10-13 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EP2255190A4 (de) * | 2008-02-12 | 2011-05-04 | Brigham & Womens Hospital | Fish-test für eml4-alk-fusion bei lungenkrebs |
| JP2009219728A (ja) * | 2008-03-18 | 2009-10-01 | Daito Giken:Kk | 遊技台 |
| WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CA2762108A1 (en) * | 2009-05-15 | 2010-11-18 | Insight Genetics, Inc. | Methods and compositions relating to fusions of alk for diagnosing and treating cancer |
| US20120202214A1 (en) * | 2009-10-06 | 2012-08-09 | Kazuya Omi | Method for detecting fusion gene |
| WO2011087709A2 (en) | 2009-12-22 | 2011-07-21 | Quest Diagnostics Investments Incorporated | Eml4-alk translocations in lung cancer |
| US9157905B2 (en) | 2010-02-22 | 2015-10-13 | Fujirebio Inc. | Method for identifying oncogene, method for establishing oncogene-expressing cell, and method of screening oncogene targeting drug |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| TW201202703A (en) * | 2010-04-16 | 2012-01-16 | Response Genetics Inc | Primers, probes, methods, and kits for the detection of EML4-ALK variants |
| WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| TWI526441B (zh) | 2010-08-20 | 2016-03-21 | 中外製藥股份有限公司 | 包含四環化合物的組成物 |
| JP5780527B2 (ja) * | 2010-09-02 | 2015-09-16 | 学校法人 久留米大学 | 単分子ｄｎａから形成される環状ｄｎａの作成方法 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| JP5769952B2 (ja) * | 2010-11-12 | 2015-08-26 | 株式会社Ｌｓｉメディエンス | Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法 |
| WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
| BR112013019643B1 (pt) * | 2011-02-02 | 2022-04-19 | Novartis Ag | Uso de inibidores de álcali |
| WO2012139134A2 (en) * | 2011-04-07 | 2012-10-11 | Coferon, Inc. | Methods of modulating oncogenic fusion proteins |
| MX360404B (es) | 2011-05-04 | 2018-10-31 | Ariad Pharma Inc | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. |
| EP2752486B1 (de) * | 2011-08-31 | 2016-12-28 | Kurume University | Verfahren zur exklusiven auswahl von zirkularisierter dna aus monomolekularer dna bei der zirkularisierung von dna-molekülen |
| PL2838998T3 (pl) | 2012-04-18 | 2018-04-30 | Cell Signaling Technology, Inc. | EGFR i ROS1 w nowotworze |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9084456B1 (en) * | 2012-05-28 | 2015-07-21 | Jack Zemer | Linkage for jewelry components |
| US9597348B2 (en) | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| JP2016510316A (ja) * | 2012-12-21 | 2016-04-07 | エピザイム，インコーポレイティド | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2015012397A1 (ja) | 2013-07-26 | 2015-01-29 | 公益財団法人がん研究会 | Ｎｔｒｋ３融合体の検出法 |
| WO2015064620A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JPWO2015064621A1 (ja) * | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JP6731254B2 (ja) | 2014-01-24 | 2020-07-29 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JP6873698B2 (ja) | 2014-04-25 | 2021-05-19 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| AU2015250574B2 (en) | 2014-04-25 | 2020-07-16 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
| TWI831347B (zh) | 2014-08-08 | 2024-02-01 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| EP2990493B1 (de) | 2014-09-01 | 2017-05-24 | ARKRAY, Inc. | Primerreagenz zur amplifikation des alk-fusionsgens, alk-fusionsgenamplifikations-reagenzienkit damit und alk-fusionsgenamplifikationsverfahren und alk-fusionsgenanalyseverfahren damit |
| WO2017122816A1 (ja) | 2016-01-15 | 2017-07-20 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JP6740172B2 (ja) * | 2017-05-02 | 2020-08-12 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| WO2020004630A1 (ja) | 2018-06-29 | 2020-01-02 | 中外製薬株式会社 | 難溶性の塩基性薬剤を含有する医薬組成物 |
| JP7385191B2 (ja) * | 2019-08-30 | 2023-11-22 | 学校法人同志社 | Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬 |
| JP2020156481A (ja) * | 2020-04-06 | 2020-10-01 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| WO2023074785A1 (ja) | 2021-10-28 | 2023-05-04 | 中外製薬株式会社 | シロップ剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60043783D1 (de) | 1999-11-11 | 2010-03-18 | Astellas Pharma Inc | Metalloprotease mit aggrecanase-aktivität |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1648455A4 (de) | 2003-07-23 | 2009-03-04 | Exelixis Inc | Anaplastische lymphom-kinase-modulatoren und anwendungsverfahren |
| WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| US7973061B2 (en) | 2004-03-31 | 2011-07-05 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| WO2008127248A1 (en) * | 2007-04-13 | 2008-10-23 | Cell Signaling Technology, Inc. | Gene defects and mutant alk kinase in human solid tumors |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
-
2007
- 2007-08-24 CA CA 2598893 patent/CA2598893C/en active Active
- 2007-08-27 US US11/845,498 patent/US7728120B2/en active Active
- 2007-10-11 EP EP20090006058 patent/EP2116553B1/de active Active
- 2007-10-11 ES ES09006058.3T patent/ES2515170T3/es active Active
- 2007-10-11 JP JP2007265917A patent/JP4303303B2/ja active Active
- 2007-10-11 AT AT07254044T patent/ATE450547T1/de not_active IP Right Cessation
- 2007-10-11 DE DE200760003543 patent/DE602007003543D1/de active Active
- 2007-10-11 ES ES07254044T patent/ES2335368T3/es active Active
-
2008
- 2008-04-10 US US12/100,595 patent/US7605131B2/en active Active
-
2009
- 2009-02-18 JP JP2009035918A patent/JP5172736B2/ja active Active
- 2009-05-15 US US12/466,920 patent/US7964710B2/en active Active
-
2011
- 2011-04-13 US US13/086,245 patent/US8197818B2/en active Active
-
2012
- 2012-05-10 US US13/468,730 patent/US9029521B2/en active Active
-
2015
- 2015-03-10 US US14/643,181 patent/US9932589B2/en active Active
-
2017
- 2017-11-13 US US15/810,918 patent/US20180066266A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2598893A1 (en) | 2008-04-11 |
| US20080090776A1 (en) | 2008-04-17 |
| EP2116553B1 (de) | 2014-07-30 |
| US20090099193A1 (en) | 2009-04-16 |
| JP2008295444A (ja) | 2008-12-11 |
| US9932589B2 (en) | 2018-04-03 |
| ES2335368T3 (es) | 2010-03-25 |
| US20180066266A1 (en) | 2018-03-08 |
| US7605131B2 (en) | 2009-10-20 |
| ES2515170T3 (es) | 2014-10-29 |
| DE602007003543D1 (de) | 2010-01-14 |
| JP2009100783A (ja) | 2009-05-14 |
| EP2116553A1 (de) | 2009-11-11 |
| US20110230545A1 (en) | 2011-09-22 |
| CA2598893C (en) | 2012-04-10 |
| US7964710B2 (en) | 2011-06-21 |
| JP4303303B2 (ja) | 2009-07-29 |
| US20100240673A1 (en) | 2010-09-23 |
| US20150184161A1 (en) | 2015-07-02 |
| US9029521B2 (en) | 2015-05-12 |
| US20130158095A1 (en) | 2013-06-20 |
| JP5172736B2 (ja) | 2013-03-27 |
| US8197818B2 (en) | 2012-06-12 |
| US7728120B2 (en) | 2010-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450547T1 (de) | Eml4-alk-fusionsgen | |
| ATE527385T1 (de) | Mit tumoren assoziierte genetische variationen | |
| DE602005009702D1 (de) | Esr1 und gebärmutterhalskrebs | |
| MY162056A (en) | Diagnosis and treatment of cancer using anti -ereg antibody | |
| MX2007012782A (es) | Metodos y acidos nucleicos para analisis de trastornos proliferativos celulares. | |
| ATE514090T1 (de) | Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen | |
| TW200745556A (en) | Biomarkers for liver fibrotic injury | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| WO2013033629A3 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| HK1115636A1 (en) | Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1 | |
| HK1102197A1 (en) | Hif prolyl hydroxylase activity assay | |
| TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
| ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
| WO2008140774A3 (en) | Methods for diagnosing and treating prostate and lung cancer | |
| ATE512215T1 (de) | Verfahren und mittel zur anreicherung, entfernung und zum nachweis von listerien | |
| WO2008073629A3 (en) | Bifunctional predictors of cancer treatment sensitivity and resistance | |
| WO2008012362A3 (en) | New protein isoforms and uses thereof | |
| WO2007103146A3 (en) | Truncated proteins as cancer markers | |
| WO2006085746A3 (en) | Diagnosis of metastases in hnscc tumours | |
| MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
| HK1136873A1 (en) | Use of nnmt as a marker for lung cancer | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. | |
| WO2004074441A3 (en) | Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto | |
| WO2009126804A3 (en) | Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis | |
| MY148542A (en) | A method for the assessment of cancer in a biological sample obtained from a subject |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |